Status:
UNKNOWN
Characterizing Spondyloarthritis With 68Ga-FAPI PET/CT
Lead Sponsor:
The First Affiliated Hospital of Xiamen University
Conditions:
Spondyloarthritis
Axial Spondyloarthritis
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
To evaluate the potential usefulness of 68Ga-FAPI PET/CT for the diagnosis, inflammation evaluation and prognosis prediction in spondyloarthritis.
Detailed Description
Spondyloarthritis (SpA) is a chronic inflammatory rheumatic disease characterized by inflammatory back pain, enthesitis, dactylitis, and the formation of syndesmophytes, all of which significantly aff...
Eligibility Criteria
Inclusion
- A diagnosis of SpA according to the ASAS (Assessment of Spondyloarthritis International Society) classification criteria for SpA.
- Adult men or women 18 and ≤ 65 years of age at the time of signing the informed consent (ICF).
- participants who were able to provide informed consent (signed by participant or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Exclusion
- Pregnancy;
- Breastfeeding;
- known allergy against FAPI;
- any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Key Trial Info
Start Date :
July 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05999643
Start Date
July 1 2023
End Date
August 1 2025
Last Update
August 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The first affiliated hospital of Xiamen University
Xiamen, Fujian, China, 361000